Delcath Systems
This article was originally published in The Gray Sheet
Executive Summary
National Cancer Institute Phase II study of the firm's catheter-based perfusion technology to deliver the chemotherapy drug melphalan will begin "shortly" to treat primary hepatic tumors and metastatic liver cancer originating from adenocarcinoma, neuro-endocrine or melanoma cancers. Data from 18 patients in the Phase I NCI study showed that more aggressive melphalan treatment is possible using the local delivery technique. Anti-tumor activity was achieved in 75%, or six of eight subjects with inoperable metastatic liver cancers that began as ocular melanoma, Delcath says...
You may also be interested in...
Grant & Licensing Opportunities In Brief
NCI shortage will not affect grants: National Cancer Institute funding of research project grants (RPG) will increase slightly and remain at 46% ($2.2 bil.) of overall budget, despite funding deficit in fiscal 2005. Although the NIH institute technically received a 1.8% budget increase in FY 2005, NCI has $62 mil. less than FY 2004 largely due to continuing RPG obligations, the agency stresses in the Jan. 18 NCI Cancer Bulletin. Reductions will take place outside of RPGs, training, cooperative research groups and specialized programs of research excellence. NCI's Board of Scientific Advisors, Board of Scientific Counselors and National Cancer Advisory Board are discussing how best to manage the remaining funds and how to continue to support new research...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.